Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Annals of Hematology

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00277-008-0585-6PMID 18726097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma

  2008cited by this paper
• Late lethal hepatitis B virus reactivation after rituximab treatment of low‐grade cutaneous B‐cell lymphoma

  2006cited by this paper
• Reactivation of hepatitis B virus with rituximab

  2005cited by this paper
• Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma

  2003cited by this paper
• Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

  2003cited by this paper
• Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

  2002cited by this paper
• Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.

  2002cited by this paper
• Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

  2001cited by this paper
• Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

  2001cited by this paper
• Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.

  2001cited by this paper
• Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

  2000cited by this paper
• Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab.

  2000cited by this paper
• Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

  1999cited by this paper

• Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma

  2021cites this paper
• Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B‐cell lymphoma in Taiwan – a population‐based study

  2020cites this paper
• Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy

  2019cites this paper
• Incidence of Hepatitis B Viral Reactivation After Kidney Transplantation With Low-Dose Rituximab Administration

  2018cites this paper
• Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER.

  2017cites this paper
• Antiviral therapies for managing viral hepatitis in lymphoma patients

  2017cites this paper
• Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders

  2016cites this paper
• Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.

  2015influential citation
• Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab

  2015cites this paper
• [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].

  2015cites this paper
• Hepatitis B virus reactivation with a rituximab-containing regimen.

  2015cites this paper
• Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy

  2014cites this paper
• Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study

  2014cites this paper
• Hepatitis B Reactivation and Rituximab: A New Boxed Warning and Considerations for Solid Organ Transplantation

  2014cites this paper
• Signal Detection of hepatitis B and hepatitis C by molecularly-targeted drugs for cancer:: Data Mining of FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report database@@@－日米の有害事象自発報告データベースを用いて－

  2014cites this paper
• A drug safety evaluation of rituximab and risk of hepatitis B

  2014cites this paper
• Treatment of rheumatic diseases and hepatitis B virus coinfection

  2014cites this paper
• Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis.

  2013cites this paper
• Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.

  2013cites this paper
• An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study

  2013cites this paper
• Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis.

  2013cites this paper
• Reactivation of hepatitis B virus in patients receiving chemotherapy.

  2013cites this paper
• Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy

  2012cites this paper
• Management of rheumatic disease with comorbid HBV or HCV infection

  2012cites this paper
• Management of hepatitis B reactivation in patients receiving cancer chemotherapy

  2012cites this paper
• Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy.

  2011cites this paper
• Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO.

  2011cites this paper
• Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.

  2011influential citation
• Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes.

  2011cites this paper
• Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma

  2010cites this paper
• Rituximab Administration and Reactivation of HBV

  2010cites this paper
• Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance

  2009cites this paper
• Prevention of hepatitis B virus reactivation under rituximab therapy.

  2009cites this paper